AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16389916 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty-free interim analysis strategies
Number of subjects: 0
Study 16389916 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivating studies
Number of subjects: 0
Study 12362231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2) 1 mg (oE(2) group, n = 37)
Number of subjects: 152
Study 12362231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2) 1 mg combined with gestodene 25 micro g (oE(2) + G group, n = 33)
Number of subjects: 152
Study 12362231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐oestradiol (E(2)) 50 micro g (tE(2) group, n = 33)
Number of subjects: 152
Study 12362231 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 152
Study 10399995 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 237
Study 10399995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 8991841 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted vaginal hysterectomy (LAVH)
Number of subjects: 70
Study 8991841 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy (abd. HE)
Number of subjects: 70
Study 1309390 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 ml of iodized oil (47 mg of iodine)
Number of subjects: 75
Study 1309390 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml of iodized oil (118 mg of iodine)
Number of subjects: 75
Study 1309390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 6697117 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrectomy and Roux‐en‐Y anastomosis (Group B)
Number of subjects: 42
Study 6697117 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication (Group A)
Number of subjects: 42
Study 31780001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray containing IND02 (100 μg/100 μL), twice a day for seven days
Number of subjects: 0
Study 31780001 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study 30165761 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Inclinometer
Number of subjects: 270
Study 30165761 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified 35° MAG
Number of subjects: 270
Study 30165761 — intervention group
Group type: COMPARATOR
Intervention: Freehand
Number of subjects: 270
Study 26985911 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent interventions to the Clinical Treatment Algorithm (CTA)
Number of subjects: 454
Study 26985911 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent interventions to the Clinical Treatment Algorithm (CTA)
Number of subjects: 454
Study 25468575 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed i-gel (42°C for 30 minutes)
Number of subjects: 68
Study 25468575 — intervention group
Group type: COMPARATOR
Intervention: Room temperature i-gel (approximately 23°C)
Number of subjects: 68
Study 22402822 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging
Number of subjects: 91
Study 20018537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 18
Study 20018537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 18
Study 20018537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral water)
Number of subjects: 18
Study 20018537 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking by parents (FTP)
Number of subjects: 18
Study 18702647 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term virological response (LTR)
Number of subjects: 202
Study 18702647 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (NR)
Number of subjects: 202
Study 18702647 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (LTR + NR)
Number of subjects: 202
Study 18702647 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for baseline risk factors
Number of subjects: 202
Study 18702647 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with IFG-DM
Number of subjects: 202
Study 15998276 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX rinsing
Number of subjects: 16
Study 15998276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 16
Study 15998276 — intervention group
Group type: EXPERIMENTAL
Intervention: EC40 varnish
Number of subjects: 16
Study 15998276 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 16
Study 12427056 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 88
Study 12427056 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 88
Study 10687503 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralizing toothpaste
Number of subjects: 50
Study 10687503 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice
Number of subjects: 50
Study 9112275 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin type V (heavily pigmented individuals)
Number of subjects: 2
Study 9112275 — intervention group
Group type: COMPARATOR
Intervention: Skin types I and II (fair-skinned individuals)
Number of subjects: 2
Study 9112275 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin type V
Number of subjects: 2
Study 1742583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunar DPX
Number of subjects: 0
Study 1742583 — intervention group
Group type: COMPARATOR
Intervention: Hologic QDR-1000
Number of subjects: 0
Study 1742583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunar DPX and Hologic QDR-1000
Number of subjects: 0
Study 7038189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefroxadine (CXD) at doses of 5, 10, and 20 mg/kg
Number of subjects: 151
Study 7038189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefroxadine (CXD)
Number of subjects: 151
Study 31116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmented and plastic hemorrhoidectomy (SPH)
Number of subjects: 300
Study 31116312 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy (Control)
Number of subjects: 300
Study 28251822 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 28
Study 28251822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26949924 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation text focusing on medication
Number of subjects: 178
Study 26949924 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation text focusing on CBT
Number of subjects: 178
Study 26949924 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation text focusing on psychodynamic therapy
Number of subjects: 178
Study 22508760 — intervention group
Group type: EXPERIMENTAL
Intervention: LDX (n = 17)
Number of subjects: 32
Study 22508760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 32
Study 22120995 — intervention group
Group type: EXPERIMENTAL
Intervention: Coroflex™ Please stents
Number of subjects: 319
Study 22120995 — intervention group
Group type: COMPARATOR
Intervention: Taxus™ Liberte stents
Number of subjects: 319
Study 20412274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily for 4 months
Number of subjects: 40
Study 20412274 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg daily for 4 months
Number of subjects: 40
Study 17394963 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise catheter ablation of chronic AF
Number of subjects: 40
Study 16277141 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment optimism
Number of subjects: 76
Study 16277141 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome expectations
Number of subjects: 76
Study 12452499 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% triclocarban-containing soap
Number of subjects: 162
Study 12452499 — intervention group
Group type: COMPARATOR
Intervention: Placebo soap
Number of subjects: 162
Study 12452499 — intervention group
Group type: COMPARATOR
Intervention: Standard practice controls
Number of subjects: 162
Study 9627917 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-based diet
Number of subjects: 45
Study 9627917 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based diet
Number of subjects: 45
Study 9627917 — intervention group
Group type: COMPARATOR
Intervention: Dairy-based control diet
Number of subjects: 45
Study 7667020 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue lenses (58% ionic)
Number of subjects: 19
Study 7667020 — intervention group
Group type: EXPERIMENTAL
Intervention: Permaflex lenses (74% non‐ionic)
Number of subjects: 19
Study 7667020 — intervention group
Group type: EXPERIMENTAL
Intervention: All three lenses (Medalist, Acuvue, Permaflex)
Number of subjects: 19
Study 2913837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal self-help smoking cessation program (8-week serialized program)
Number of subjects: 242
Study 2913837 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 242
Study 30012494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-literacy chronic pain self-management program delivered in 6 sessions of 1-on-1 meetings with a trained health educator
Number of subjects: 111
Study 30012494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-literacy chronic pain self-management program delivered in 8 group lectures by experts
Number of subjects: 111
Study 30012494 — intervention group
Group type: COMPARATOR
Intervention: Both arms of the intervention (1-on-1 and group lectures)
Number of subjects: 111
Study 28342943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics for schizophrenia
Number of subjects: 1807
Study 28342943 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived treatability and belief in effectiveness of treatment for schizophrenia
Number of subjects: 1807
Study 28342943 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived treatability and belief in effectiveness of treatment for depression
Number of subjects: 1807
Study 28342943 — intervention group
Group type: COMPARATOR
Intervention: Somatic illnesses
Number of subjects: 1807
Study 26651484 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change strategy consisting of one individual theoretical counseling session plus eight twice-a-week individual theoretical and practical exercise counseling sessions for 3 years.
Number of subjects: 300
Study 26651484 — intervention group
Group type: COMPARATOR
Intervention: Standard care including general physician recommendations for daily PA.
Number of subjects: 300
Study 23179024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagic DMD patients
Number of subjects: 27
Study 23179024 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 23179024 — intervention group
Group type: COMPARATOR
Intervention: Preserved swallow function DMD patients
Number of subjects: 27
Study 21349479 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 80
Study 21349479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19036671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 100 mg/day (100 mg initial dose, then 50 mg intravenously twice daily)
Number of subjects: 546
Study 19036671 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 2 g/day (1 g intravenously twice daily) and Aztreonam 4 g/day (2 g intravenously twice daily)
Number of subjects: 546
Study 19036671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 546
Study 19036671 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin/Aztreonam
Number of subjects: 546
Study 16609033 — intervention group
Group type: EXPERIMENTAL
Intervention: High LET carbon beam therapy
Number of subjects: 49
Study 12900739 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-NORM interpretation of SPECT images
Number of subjects: 258
Study 12900739 — intervention group
Group type: EXPERIMENTAL
Intervention: POST-NORM interpretation of SPECT images
Number of subjects: 258
Study 12900739 — intervention group
Group type: COMPARATOR
Intervention: Control group (single-vessel CAD)
Number of subjects: 258
Study 12900739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no significant angiographic CAD)
Number of subjects: 258
Study 12900739 — intervention group
Group type: COMPARATOR
Intervention: Control group (normalcy group)
Number of subjects: 258
Study 10971327 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based disinfectant
Number of subjects: 52
Study 10971327 — intervention group
Group type: COMPARATOR
Intervention: Non-antiseptic soap
Number of subjects: 52
Study 8929043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac infusion (150 mg in 60 ml isotonic chlorinated solution at 0.5 ml/h + 4 bolus/h of 0.5 ml)
Number of subjects: 36
Study 8929043 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion (60 ml in 60 ml isotonic chlorinated solution at the same rate)
Number of subjects: 36
Study 8929043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (60 ml isotonic chlorinated solution + Ketorolac intramuscular on demand)
Number of subjects: 36
Study 1639742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 785
Study 1639742 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 785
Study 6375805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloxolone cream
Number of subjects: 79
Study 6375805 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone cream
Number of subjects: 79
Study 6375805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 31393176 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) for 2 weeks
Number of subjects: 1800
Study 31393176 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 1800
Study 30219432 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (10 g pre-mixed in cookies twice per day for 12 weeks)
Number of subjects: 51
Study 30219432 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 51
Study 30219432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27004570 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg IV)
Number of subjects: 206
Study 27004570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 27004570 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 206
Study 27004570 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 and Placebo
Number of subjects: 206
Study 24519768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography (five annual mammography screens)
Number of subjects: 89835
Study 24519768 — intervention group
Group type: COMPARATOR
Intervention: Control (no mammography)
Number of subjects: 89835
Study 22500643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking blood at Neiyingxiang (ExHN 9)
Number of subjects: 50
Study 22500643 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture treatment at Waiyingxiang (LI 20)
Number of subjects: 50
Study 20605871 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB with low tidal volume ventilation (3 ml.kg(‐1)) without positive end expiratory pressure (PEEP)
Number of subjects: 40
Study 20605871 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no ventilation during CPB)
Number of subjects: 40
Study 17433950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of enalaprilat
Number of subjects: 22
Study 17433950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15818198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year cognitive-behavioral stress management program
Number of subjects: 166
Study 15818198 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study 11971197 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment schedule of melarsoprol (10 daily doses of 2.16 mg/kg)
Number of subjects: 500
Study 11971197 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol of melarsoprol (3 series of 3-4 injections every 24 hours)
Number of subjects: 500
Study 11971197 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment schedule of melarsoprol
Number of subjects: 500
Study 11971197 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol of melarsoprol
Number of subjects: 500
Study 9565948 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-bout exercise condition (30 min continuous session per day)
Number of subjects: 50
Study 9565948 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-bout exercise condition (three 10-min sessions per day)
Number of subjects: 50
Study 7797653 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy
Number of subjects: 0
Study 7797653 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive therapy
Number of subjects: 0
Study 1972434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1‐0.2 mg/kg) administered by rapid injection (30 s)
Number of subjects: 13
Study 1972434 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1‐0.2 mg/kg) administered by slow infusion (20‐30 min)
Number of subjects: 13
Study 1972434 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 354373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 45
Study 354373 — intervention group
Group type: COMPARATOR
Intervention: Neomycin-sorbitol
Number of subjects: 45
Study 30905614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clementines (1 kg/d)
Number of subjects: 2
Study 30905614 — intervention group
Group type: EXPERIMENTAL
Intervention: Clementine juice (chronic consumption)
Number of subjects: 2
Study 29127080 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg ENDS
Number of subjects: 68
Study 29127080 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg ENDS
Number of subjects: 68
Study 29127080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 29127080 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ENDS groups
Number of subjects: 68
Study 29127080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation behaviors (quit attempts, biologically verified abstinence)
Number of subjects: 68
Study 26578308 — intervention group
Group type: EXPERIMENTAL
Intervention: Common beans
Number of subjects: 0
Study 26578308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cowpeas
Number of subjects: 0
Study 26578308 — intervention group
Group type: COMPARATOR
Intervention: Standard complementary food
Number of subjects: 0
Study 23145889 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported recommendations for follow-up after abnormal Pap tests
Number of subjects: 519
Study 23145889 — intervention group
Group type: COMPARATOR
Intervention: Health department recommendations for follow-up after abnormal Pap tests
Number of subjects: 519
Study 23145889 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving a letter stating the results of the Pap test
Number of subjects: 519
Study 23145889 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a gynecologist for follow-up
Number of subjects: 519
Study 21555982 — intervention group
Group type: EXPERIMENTAL
Intervention: Training the healthy hand to execute the nine hole peg test 10 times a day for three consecutive days.
Number of subjects: 20
Study 21555982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 20
Study 18438407 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs4415084
Number of subjects: 6145
Study 18438407 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs10941679
Number of subjects: 6145
Study 18438407 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR2 signal
Number of subjects: 6145
Study 15774846 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg rhCC10
Number of subjects: 22
Study 15774846 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg rhCC10
Number of subjects: 22
Study 15774846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11893369 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid‐enriched diets
Number of subjects: 15806
Study 10211913 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatosetron 0.2 mg
Number of subjects: 43
Study 10211913 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatosetron 1 mg
Number of subjects: 43
Study 10211913 — intervention group
Group type: EXPERIMENTAL
Intervention: Zatosetron 5 mg
Number of subjects: 43
Study 10211913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 7789938 — intervention group
Group type: EXPERIMENTAL
Intervention: McCanse Readiness for Death Instrument (MRDI) administered to terminally-ill individuals
Number of subjects: 70
Study 7789938 — intervention group
Group type: COMPARATOR
Intervention: McCanse Readiness for Death Instrument (MRDI) administered to cardiac-impaired individuals (control group)
Number of subjects: 70
Study 1975995 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol
Number of subjects: 20
Study 354312 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of calcium per day
Number of subjects: 40
Study 354312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31471436 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerised cognitive training (CCT) with exercises targeting memory, matching, spatial recognition, processing speed for 12 weeks followed by booster sessions up to 78 weeks.
Number of subjects: 100
Study 31471436 — intervention group
Group type: COMPARATOR
Intervention: Home-based active control condition (computerised crossword puzzle training (CPT)) for 12 weeks followed by booster sessions up to 78 weeks.
Number of subjects: 100
Study 28975634 — intervention group
Group type: EXPERIMENTAL
Intervention: CTI ablation with continuous reevaluation of the CTI block during 30 minutes (WT+ group)
Number of subjects: 319
Study 28975634 — intervention group
Group type: COMPARATOR
Intervention: CTI ablation with no waiting period after proven bidirectional CTI block (WT- group)
Number of subjects: 319
Study 26015558 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy for Diabetes (BFST‐D)
Number of subjects: 0